[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352388-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352388-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","identication-of-small-molecule-inhibitors-targeting-fgfr-through-molecular-docking-based-screening","Identiﬁcation of small molecule inhibitors targeting FGFR through molecular docking-based screening","","FGFR genetic alterations, including mutations, amplifications, and chromosomal translocations, are common in cancers and drive tumor initiation and progression through enhanced FGFR signaling. Limited decisive clinical evidence has halted some inhibitor uses, motivating the search for selective small-molecule FGFR inhibitors. The study uses FGFR1/2/3/4 structures from PDB and ZINC15 small molecules with molecular docking and dynamics simulations, then validates effects in CRC cell lines.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/identication-of-small-molecule-inhibitors-targeting-fgfr-through-molecular-docking-based-screening/352388/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/identication-of-small-molecule-inhibitors-targeting-fgfr-through-molecular-docking-based-screening/352388.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does this study address about FGFR inhibitors?","Question",{"text":63,"@type":64},"It addresses the lack of decisive clinical evidence for some existing FGFR inhibitor applications and the need to identify effective small-molecule inhibitors that selectively target FGFRs.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were candidate compounds selected in the study?",{"text":68,"@type":64},"FGFR1/2/3/4 structures and tyrosine kinase domain amino acid positions were obtained from PDB, small molecules were extracted from ZINC15, and molecular docking plus dynamics simulations were used to assess FGFR interactions.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main findings from the docking and cellular evaluation?",{"text":72,"@type":64},"Docking identified three promising FGFR small-molecule inhibitors ranked by free-energy metrics; ZINC000101867325 showed stable interactions with FGFR1/2/3 and inhibited FGFR signaling, leading to apoptosis and reduced proliferation and migration in colorectal cancer cell lines.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352388,1790622501,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","TYPE Original Research PUBLISHED 29 January 2026 DOI 10.3389/fonc.2026.1733391  \nOPEN ACCESS  \nEDITED BY  \nBekir Cinar,  \nPh. D., Clark Atlanta University, United States  \nREVIEWED BY  \nOlubukola Titilope Oyebode, University of Derby, United Kingdom Hai-Anh Ha,  \nDa Nang University of Medical Technology and Pharmacy, Vietnam  \n*CORRESPONDENCE  \nQingran Kong  \n [kqr721726@163.com](kqr721726@163.com)[ ](kqr721726@163.com)Xinyu Wang  \n[wangxinyuhs@126.com](wangxinyuhs@126.com)[ ](wangxinyuhs@126.com)Qi Zhao  \n [zq920@163.com](zq920@163.com)[ ](zq920@163.com)Liang Cheng  \n [liangcheng@hrbmu.edu.cn](liangcheng@hrbmu.edu.cn)  \n†These authors have contributed equally to this work  \nRECEIVED 30 October 2025  \nREVISED 30 December 2025  \nACCEPTED 06 January 2026  \nPUBLISHED 29 January 2026  \nCITATION  \nHou W, Liu K, Wang P, Zheng K, Kong Q, Wang X, Zhao Q and Cheng L (2026)  \nIdentiﬁcation of small molecule inhibitors targeting FGFR through molecular docking-based screening.  \nFront. Oncol. 16:1733391 .  \ndoi: 10.3389/fonc.2026.1733391  \nCOPYRIGHT  \n© 2026 Hou, Liu, Wang, Zheng, Kong, Wang, Zhao and Cheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nIdentiﬁcation of small molecule inhibitors targeting FGFR through molecular dockingbased screening  \nWeibo Hou 1†, Kun Liu 2†, Ping Wang 1†, Kefan Zheng 3,  \nQingran Kong 4*, Xinyu Wang 5*, Qi Zhao 6* and Liang Cheng 1*  \n1College of Bioinformatics Science and Technology, National Health Commission Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, Harbin Medical University, Harbin, Heilongjiang, China, 2 Department of Oncology, Heilongjiang Academy of Traditional Chinese Medicine, Harbin, Heilongjiang, China, 3Zhejiang Provincial Key Laboratory of Medical Genetics, Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China, 4West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China, 5 Institute for Regenerative Medicine, Shanghai East Hospital, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, China, 6 Department of Cardiology, Ningbo Medical Center, The Afﬁliated LiHuiLi Hospital of Ningbo University, Ningbo, Zhejiang, China  \nBackground: FGFRs genetic alterations such as mutations, ampliﬁcations, and chromosomal translocations are prevalent in cancers, leading to the initiation and progression of tumors by enhancing FGFR signaling. The substantial problems arising from the lack of decisive clinical evidence have resulted in the cessation of some inhibitor applications, and identifying effective small molecule inhibitors that selectively target FGFRs can advance the therapy of cancers driven by FGFRs abnormalities.  \nMethods: The three-dimensional structure of the FGFR1/2/3/4 protein and the amino acid positions within the tyrosine kinase domain were downloaded from the PDB database, and small molecule data were extracted from the ZINC15 database. Then, we used molecular docking and dynamics simulations to assess compounds interacting with FGFR proteins, and screening potential small molecules targeting FGFR. Finally, we evaluated its effects by two CRC cell line HCT116 and NCI-H716 .  \nResults: In the study, by docking with 2 . 8 million small molecules, we identiﬁed three promising FGFR small molecule inhibitors ranked in the top average absolute difference in free energy. By evaluating the binding stability of the docking pose of the three compounds, we found tha","cbCaiafqKSNKC0Eq","https://ap.wps.com/l/cbCaiafqKSNKC0Eq","pdf",11335780,13,"English","# Background\n# Methods\n# Results\n# Conclusion\n# Key words\n# 1 Introduction","[{\"question\":\"What problem does this study address about FGFR inhibitors?\",\"answer\":\"It addresses the lack of decisive clinical evidence for some existing FGFR inhibitor applications and the need to identify effective small-molecule inhibitors that selectively target FGFRs.\"},{\"question\":\"How were candidate compounds selected in the study?\",\"answer\":\"FGFR1/2/3/4 structures and tyrosine kinase domain amino acid positions were obtained from PDB, small molecules were extracted from ZINC15, and molecular docking plus dynamics simulations were used to assess FGFR interactions.\"},{\"question\":\"What were the main findings from the docking and cellular evaluation?\",\"answer\":\"Docking identified three promising FGFR small-molecule inhibitors ranked by free-energy metrics; ZINC000101867325 showed stable interactions with FGFR1/2/3 and inhibited FGFR signaling, leading to apoptosis and reduced proliferation and migration in colorectal cancer cell lines.\"}]","Identiﬁcation of small molecule inhibitors targeting FGFR through molecular docking-based screening | PDF",1790099314,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dfb4b5f6893e9b0f16dd3a2a24120f64.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/007126e346fd8ca950a84ed51fd347b8.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00fc3a2d6933548a28fed8ecc6d75eaa.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3bf9f766bb16016be72249671c32b318.webp",980,1385]